arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive Leaguearthyper-1011Research ArticleНОВОСТИ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ30-летний юбилей нифедипина. Новые исследования открывают новые возможностиКонрадиА. О.noemail@neicon.ruНИИ кардиологии им. В.А.Алмазова М3 и СР РФРоссия2005280220051115962Copyright © Конради А.О., 20052005Конради А.О.Конради А.О.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1011ReferencesMac Mahon N.B., Саитап S. Effects of АСЕ inhibitors, calcium antagonists, and other blood pressure lowering drugs results of prospectively designed overviews of randomized trials BPLTCT Lancet 2004, 345 1076-78Mac Mahon N.B., Саитап S. Effects of АСЕ inhibitors, calcium antagonists, and other blood pressure lowering drugs results of prospectively designed overviews of randomized trials BPLTCT Lancet 2004, 345 1076-78Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic m the International Nifedipine GITS Study Intervention as a Goal in Hypertensive Treatment (INSIGHT) Lancet 2000, 356 366-72Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double-Blind Treatment with Long-Acting Calcium Channel Blockers or Diuretic m the International Nifedipine GITS Study Intervention as a Goal in Hypertensive Treatment (INSIGHT) Lancet 2000, 356 366-72Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002, 288, 2981-79Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and Lipid lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002, 288, 2981-79Guidelines Committee 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension J Hypertension 2003, 21 1011 -53Guidelines Committee 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension J Hypertension 2003, 21 1011 -53Joint National Committee 2003 report of the Report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC VII) JAMA 2003, 255-61Joint National Committee 2003 report of the Report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC VII) JAMA 2003, 255-61World Health Organization (WHO)/international Society of Hypertension (ISH) statement on management of hypertension J Hypertension 2003, 21 1983-92World Health Organization (WHO)/international Society of Hypertension (ISH) statement on management of hypertension J Hypertension 2003, 21 1983-92Agabiti-Rosei E., Zulli R., Muiesan M. et al. Reduction of cardiovascular structural changes by nifedipine GITS m essential hypertensive patients Blood Pressur 1998, 7(3) 160-9Agabiti-Rosei E., Zulli R., Muiesan M. et al. Reduction of cardiovascular structural changes by nifedipine GITS m essential hypertensive patients Blood Pressur 1998, 7(3) 160-9Pitt B., Byington R.P., Rurberg C.D. et al. Effect of amlodipme on the progression of atherosclerosis and the occurrence of clinical events PREVENT investigators Circulation 2000, 102 1503-10Pitt B., Byington R.P., Rurberg C.D. et al. Effect of amlodipme on the progression of atherosclerosis and the occurrence of clinical events PREVENT investigators Circulation 2000, 102 1503-10Motro M., Shemesh J. Calcium channel blocker slows the progression of early coronary calcification m hypertensive patients compared with diuretics Hypertension 2001, 37 1410-1403Motro M., Shemesh J. Calcium channel blocker slows the progression of early coronary calcification m hypertensive patients compared with diuretics Hypertension 2001, 37 1410-1403Simon A., Ganepy J., Moyse D. et al. Different effects ofnifedipme and co-amilozide on the progression of early carotid wall changes Circulation 2001, 103 2949-54Simon A., Ganepy J., Moyse D. et al. Different effects ofnifedipme and co-amilozide on the progression of early carotid wall changes Circulation 2001, 103 2949-54Virdis A., Taddei S. et al. Nifedipine improves endothelium dependent vasodilatation by restoring nutric oxide Am J Hypertens 1999, 12 (Suppl) 57AVirdis A., Taddei S. et al. Nifedipine improves endothelium dependent vasodilatation by restoring nutric oxide Am J Hypertens 1999, 12 (Suppl) 57AHempel A., Lindschau C., Maasch C., et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase С Circulation 1999,99 2523-2529Hempel A., Lindschau C., Maasch C., et al. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase С Circulation 1999,99 2523-2529Ghiadom L., Magagna A., Versan D. et al. Different effect of antihypertensive drugs on conduit artery endothelial function Hypertension 2003,41 1281-1286Ghiadom L., Magagna A., Versan D. et al. Different effect of antihypertensive drugs on conduit artery endothelial function Hypertension 2003,41 1281-1286Verhaar M.C., Honing M.L., van Dam T et al. Nifedipine improves endothelial function m hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res 1999, 42 752-60Verhaar M.C., Honing M.L., van Dam T et al. Nifedipine improves endothelial function m hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res 1999, 42 752-60Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease Circ Res 2001,89 El-7Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease Circ Res 2001,89 El-7The ENCORE investigators Effect of nifedipine and cenvastatmeon coronary endothelial function in patients with coronary artery disease, Circulation 203, 107 422-8The ENCORE investigators Effect of nifedipine and cenvastatmeon coronary endothelial function in patients with coronary artery disease, Circulation 203, 107 422-8Poole-Wuilson P.A., Lublen J., Kirwan B.A. et al. Coronary disease trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators Effect of long-term nifedipine on mortality and cardiovascular morbidity m patients with stable angina requiring treatment (ACTION trial) randomized controlled trail Lancet 2004, 364 849-57Poole-Wuilson P.A., Lublen J., Kirwan B.A. et al. Coronary disease trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators Effect of long-term nifedipine on mortality and cardiovascular morbidity m patients with stable angina requiring treatment (ACTION trial) randomized controlled trail Lancet 2004, 364 849-57Lubsen J., Wagener G., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stale angina and hypertension the ACTION trial J Hypertens 2005 (in press)Lubsen J., Wagener G., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stale angina and hypertension the ACTION trial J Hypertens 2005 (in press)
The authors declare that there are no conflicts of interest present.